Sat, Jul 26, 2014, 2:25 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Central Fund of Canada Limited (CEF) Message Board

bucket_shop_player 7 posts  |  Last Activity: Jul 24, 2014 8:45 AM Member since: Dec 11, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bucket_shop_player bucket_shop_player Jul 24, 2014 8:45 AM Flag

    BS the only thing not working here is your brain - if the cure did not work, it would not have gotten passed the FDA, at least not with claims of cure and no one would pay $84K for treatments that do not work especially not medicare or insurance carriers - personally know of 2 people cured by Sovaldi

    Sentiment: Strong Buy

  • Reply to

    Buy on this dip...

    by akadvisor2020 Jul 23, 2014 6:06 PM
    bucket_shop_player bucket_shop_player Jul 24, 2014 8:30 AM Flag

    I am guessing your crystal ball is either out of warranty or broken good luck with that short

    Sentiment: Strong Buy

  • Reply to

    Current Price

    by jjkon2525 Jul 23, 2014 9:38 PM
    bucket_shop_player bucket_shop_player Jul 23, 2014 9:53 PM Flag

    Not true but even if it was they did nt include this Gilead didn't include in its guidance sales of a new blood-cancer drug, which the FDA approved Wednesday. Analysts estimate the pill, Zydelig, will have about $1 billion in sales in 2017. It marks Gilead's first medicine for cancer, another disease it's targeting. GOOD LUCK SHORTY

  • bucket_shop_player bucket_shop_player Jul 23, 2014 9:01 PM Flag

    This is an asinine way to look at this - what is $84K for a treatment that works vs the cost of chronic care for a disease that lasts a long time and kills the patient vs cure. The insurers should look at the costs of chronic care let alone the cost of a liver transplant vs teh cure - the Solvadi treatment is a bargain by those metrics. Yes, its sticker shock, but its only because they are not tabulated the true costs of the non cure alternatives

    Sentiment: Strong Buy

  • bucket_shop_player bucket_shop_player Jul 23, 2014 8:09 PM Flag

    And don't forget this --- Gilead didn't include in its guidance sales of a new blood-cancer drug, which the FDA approved Wednesday. Analysts estimate the pill, Zydelig, will have about $1 billion in sales in 2017. It marks Gilead's first medicine for cancer, another disease it's targeting.

    Sentiment: Strong Buy

  • bucket_shop_player bucket_shop_player Jul 1, 2014 3:48 PM Flag

    Dream on shorty --- DG is back to where it started before the Icahn nonsense - that was total BS FDO is an albatross and any analyst that thought there would be synergies is nucking futs! The model for FDO is very different from that of the DG and it is reflected in DGs multi year out performance of FDO. The sell off was pretty extreme and wiped out that BS premium which is beyond comprehension why it was given in the first place since taking on FDO would have done much more harm than good. DG will base with an upward bias now if you are short then I wish you luck because you are going to need it also have fun paying the divy. The overreaction to the upside has been corrected with an overreaction to the downside now she will run on her own merits buying from $55 to here is more like shooting shorts in a barrel GLTA

    Sentiment: Strong Buy

  • bucket_shop_player by bucket_shop_player May 1, 2014 12:21 PM Flag

    The Barrons article tarred the entire sector because of 1 company Hornbeck and their miss. The theory is that because Hornbeck missed they will all do poorly going forward. Moreover, If I recall they had said that day rates were going to continue to fall yet DO reported strengthening day rates -- who you going to trust eggheads at Barrons or the people making their living off the day rates. He then goes on to quote ANALysts who have a less than stellar view on the sector, plus they compare apples to oranges regarding equipment. Of course the ANLysts were saying the same thing about DO before the last earnings report and how many of them were correct??? Buehller?? anyone?? - ZERO they all got blown out---I will put my money on the Tisch Family to successfully navigate and reward shareholders like they recently did. The Barrons article is a poorly concocted and lazy piece designed to get clicks rather than present any valuable information to an investor. With reporting like that I would cancel my subscription - lets see if their $75 oil prediction comes true too LOL Pathetic reporting Barrons and more pathetic people that sell their shares like sheeple with out thinking if what is wrtitien is accurate or even applies to their specific holdings - Baaaa Baaa sheeple

    Sentiment: Strong Buy

CEF
14.18+0.15(+1.07%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.